

**Drissana T Tran, M.D.**  
Oregon Center for Clinical Investigations, Inc.  
702 Church Street NE  
Salem, OR 97301

**CONTACT INFORMATION:**

Site Selection and Information:  
Bobbie Theodore, Alliance Director  
Tel. (916) 939-6696  
Fax (208) 575-3169  
Email: clinicaltrials@alliancesites.com

Site Contact:  
Kristine L. Kowalski, BS,  
Tel: 503-540-0100  
Fax: 503-540-0300  
Email: Kristine.Kowalski@occi.org

**AFFILIATIONS:**

Oregon Center for Clinical Investigations, Inc.  
905 SE 14th Avenue  
Portland, OR 97214

Oregon Center for Clinical Investigations, Inc.  
572 W 11th Avenue  
Eugene, OR 97401

Willamette Valley Hospice  
1015 3rd Street NW  
Salem, OR 97304

Salem Hospital  
890 Oak Street SE  
Salem, OR 97301

**EDUCATION:**

09/88 - 06/92 Doctor of Medicine  
Oregon Health Sciences University, Portland, OR

09/84 - 06/88 BA, Chemistry  
Robert D. Clark Honors College, University of Oregon, Eugene, OR

**RESIDENCY:**

06/92 - 07/95 Residency, Department of Internal Medicine  
Emanuel and Good Samaritan Hospitals, Portland, OR

**LICENSURE:**

Oregon State Medical License, #MD18331, 1993 - Present  
Board Eligible, Internal Medicine

**PROFESSIONAL EXPERIENCE:**

*Investigator*, 04/2016 - Present  
Oregon Center for Clinical Investigations, Inc., Salem, OR

*Hospice and Palliative Care Practice*, 03/2007 - Present  
Willamette Valley Hospice, Salem, OR

*Associate Staff Physician*, 09/2001 - Present  
Salem Hospital, Salem, OR

*Life Insurance Examiner*, 11/2006 - 02/2007  
Northwest Parmedical, Inc., Beaverton, OR

*Sub-Investigator and Study Coordinator*, 04/2002 - 10/2006  
Congestive Heart Failure Patients and Cardiac Clinical Trials, Salem Hospital Ambulatory  
Parenteral Enteral Services (SHAPES), Salem Heart Improvement Program, Salem, OR

*Sub-Investigator and Study Coordinator*, 04/2002 - 10/2006  
Congestive Heart Failure Patients and Cardiac Clinical Trials, Salem Hospital Ambulatory  
Parenteral Enteral Services (SHAPES), Salem Heart Improvement Program, Keizer, OR

*Investigator*, 10/2000 - 09/2006  
Oregon Center for Clinical Investigations, Inc., Salem, OR

*Medical Director*, 02/1999 - 07/2000  
HealthSouth Rehabilitation Center, Portland, OR

*Investigator/ Internal Medicine Practice*, 02/1999 - 07/2000  
Westover Heights Clinic, Portland, OR

*Internal Medicine Practice*, 09/1995 - 10/1998  
HealthFirst Medical Group, Tualatin, OR

*Medical Consultant, Psychiatric Patients*, 10/1994 - 06/1995  
CareMark Behavioral Health, Emanuel Hospital, Portland, OR

*Travel Medicine*, 07/1993 - 06/1995  
Travel Clinical & Urgent Care Clinic, Good Samaritan Hospital, Portland, OR

**INVESTIGATOR EXPERIENCE:**

ADHD • Alzheimer's Disease • Anorexia Nervosa • Anxiety  
Binge Eating Disorder • Bipolar Disorder • Cholesterol • Chronic Bronchitis  
Depression • Fibromyalgia • Hypertension • Insomnia • Men's Health  
Migraine • Neuropathic Pain • Opioid Induced Bowel Dysfunction  
Oppositional Defiant Disorder • Panic Disorder  
Premenstrual Dysphoric Disorder • PTSD •  
Seasonal Affective Disorder • Sexual Functioning / Dysfunction

**CLINICAL TRIAL EXPERIENCE:**

***ADHD***

A Phase III, Multicenter, Dose-Optimized, Open-Label Safety Study with XXX in Children with Attention-Deficit/Hyperactivity Disorder

A Multicenter, 6-Week, Double-blind, Randomized, Placebo-controlled, Parallel-design Study to Assess the Efficacy and Safety of Drug in Adolescents (Ages 12-17 Years) with Genetic Disorders Impacting Metabotropic Glutamate Receptors and Attention Deficit Hyperactivity Disorder. (MG.102) 2016

A Noninterventional Genotype/Phenotype Study of mGluR Mutations in Children and Adolescents with Attention Deficit Hyperactivity Disorder (ADHD). (MG.101) 2016

Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Drug for the Treatment of Pediatric Patients with Attention Deficit/Hyperactivity Disorder (ADHD). (SP.102) 2016

Evaluation of Drug Efficacy and Safety in Children with ADHD - A Double-Blind, Placebo-Controlled, Dose-Ranging Study. (SP.101) 2016

A 6-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Randomized-Withdrawal Study to Evaluate the Continued Efficacy of Drug Treatment at Dosages up to 425 mg/day in Patients with Attention-Deficit Hyperactivity Disorder Who are Responders to Drug Treatment, Followed by a 12-Month, Open-Label Extension Period. (CP.113) 2006

A Phase III, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Parallel-Group, Forced-Dose Titration, Safety and Efficacy Study of Drug in Adults with Attention-Deficit Hyperactivity Disorder (ADHD). (SH.115) 2005

A Phase III, Multi-Center, 12-Month, Open-Label, Safety and Efficacy Study of Drug in Adults with Attention-Deficit Hyperactivity Disorder (ADHD). (SH.116) 2005

A Long-Term, Open-Label, and Single-Arm Study of Drug 30mg, 50mg, or 70mg per Day in Children Aged 6-12 Years with Attention Deficit Hyperactivity Disorder (ADHD). (NR.102) 2004

**CLINICAL TRIAL EXPERIENCE (*continued*):**

A Phase III, Multi-Center, Open-Label Study of Drug vs. Drug in Pediatric Patients Aged 6-13 with Attention-Deficit Hyperactivity Disorder (ADHD). (SH.110) 2004

A Phase III, Randomized, Multi-Center, Double-Blind, Parallel-Group, Placebo-Controlled Study of Drug in Children Aged 6-12 Years with Attention Deficit Hyperactivity Disorder (ADHD). (NR.101) 2004

A Phase III, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled, Dose-Optimization Study Designed to Evaluate the Safety and Efficacy of Drug vs. Drug in Pediatric Patients Aged 6-12 with Attention Deficit Hyperactivity Disorder (ADHD). (SH.109) 2004

A Phase III, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Parallel-Group, Safety and Efficacy Study of Drug with an Open Label Extension in Adolescents with Attention-Deficit Hyperactivity Disorder (ADHD). (SH.111) 2004

A Phase III, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Parallel-Group, Safety and Efficacy Study of Drug with an Open Label Extension in Adults with Attention-Deficit Hyperactivity Disorder (ADHD). (SH.113) 2004

A Phase IIIb, Open-Label, Multi-Center Study to Assess Safety, Tolerability, and Effectiveness Associated with the Use of Drug in Adults with Attention Deficit Hyperactivity Disorder and Evaluate an ADHD-specific Novel Quality of Life Measure. (SH.108) 2004

A 1-Year, Open-Label, Flexible-Dosage Study to Evaluate the Safety and Continued Efficacy of Drug (Film-Coated Tablet Formulation) in Children and Adolescents with Attention Deficit Hyperactivity Disorder (ADHD). (CP.106) 2003

A 9-Week, Randomized, Double-Blind, Placebo-Controlled, Fixed-Dosage (340 or 425 mg/day), Parallel-Group Study to Evaluate the Efficacy and Safety of Drug (Film-Coated Tablet) in Children and Adolescents with Attention Deficit Hyperactivity Disorder (ADHD), Including a 2-Week (Blinded) Withdrawal Period. (CP.104) 2003

A Phase III, Multi-Center, 18-Month, Open-Label Safety, Tolerability, and Efficacy Study of Drug in the Treatment of Adolescents Aged 13-18 with Attention Deficit Hyperactivity Disorder (ADHD). (SH.107) 2003

A Phase III, Randomized, Multi-Center, Double-Blind, Parallel-Group, Placebo-Controlled, Safety and Efficacy Study of Drug with an Open Label Extension, in the Treatment of Adolescents Aged 13-17 with Attention Deficit Hyperactivity Disorder (ADHD). (SH.106) 2003

A Phase II, Randomized, Multi-Center, Double-Blind, Parallel-Group, Placebo-Controlled Safety and Efficacy Study of Drug in Adults Aged 18-55 with Attention Deficit Hyperactivity Disorder (ADHD). (SH.105) 2003

**CLINICAL TRIAL EXPERIENCE (*continued*):**

A Phase III, Open-Label Study of Drug in Children and Adolescents (Aged 6-17) with Attention Deficit Hyperactivity Disorder (ADHD). (SH.104) 2003

A Phase III, Randomized, Multi-Center, Double-Blind, Parallel-Group, Placebo-Controlled, Safety and Efficacy Study of Drug in Children and Adolescents Aged 6-17 with Attention Deficit Hyperactivity Disorder (ADHD). (SH.103) 2003

A 4-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel Study to Evaluate the Efficacy and Safety of Drug in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder, Followed by an 8-Week, Open-Label Extension. (CP.101) 2002

A Multi-Center, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Drug in Pediatric Patients with Attention Deficit Hyperactivity Disorder. (NP.103) 2001

A Long-Term, Open-Label, Study of Drug in Pediatric Patients with Attention Deficit Hyperactivity Disorder. (NP.102) 2000

***Alzheimer's Disease***

A Double-Blind, Placebo-Controlled, Dose-Finding Study Evaluating the Safety and Efficacy of Drug, 80 m B.I.D., and 20 and 80 mg Q.D. in the Treatment of Mild to Moderate Alzheimer's Disease. (MI.101) 2003

A Long-Term, Open-Label Extension Study of Drug in Patients with Mild to Moderate Alzheimer's Disease. (FS.102) 2001

A Well-Controlled Safety and Efficacy Study of Drug in Patients with Mild to Moderate Alzheimer's Disease. (FS.101) 2001

***Anxiety***

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Drug in Patients with Generalized Anxiety Disorder (GAD). (PP.101) 2005

A 12-Month, Open-Label, Flexible-Dosage Study to Evaluate the Safety and Efficacy of Drug Treatment (up to 16mg/day) in Adults with Generalized Anxiety Disorder. (CP.112) 2005

A 10-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dosage Study to Evaluate the Efficacy and Safety of Drug (up to 16mg/day) in the Treatment of Adults with Generalized Anxiety Disorder. (CP.109) 2004

**CLINICAL TRIAL EXPERIENCE (*continued*):**

A Phase III, 10-Week, Double-Blind, Randomized, Placebo-Controlled Study of Drug 60 to 120 mg Once Daily (QD) or Placebo in Patients with Generalized Anxiety Disorder (GAD). (EL.105) 2004

An Open-Label Safety Study of Drug (4 to 16 mg BID) for Patients Completing Previous Drug Anxiety or Affective Disorder Studies. (EL.103) 2003

A Phase III, Randomized, Multi-Center, Double-Blind, Parallel, Placebo-Controlled, 6- to 10-Week Study Comparing the Efficacy and Safety of Drug (16 to 32 mg Once Daily [QD]) in Patients with Generalized Anxiety Disorder. (EL.102) 2003

A Four-Week, Double-Blind, Placebo- and Active-Controlled, Dose-Ranging Study of Drug 3 Doses (5, 15, 50 mg/day) and Drug (3 mg/day) in Out-Patients with General Anxiety Disorder (GAD). (SS.101) 2003

An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dosage Study to Evaluate the Efficacy and Safety of Drug, at Dosages up to 16 mg/day, in the Treatment of Generalized Anxiety Disorder in Adults. (CP.103) 2003

Drug 60 mg (or 30 mg) Once Daily in the Treatment of Generalized Anxiety Disorder. An Open-Label, Multi-Center, Safety Study of 5 Months, including a 1-Month Drug-Free Follow-up Period. (PM.109) 2002

Drug 30 mg and Drug 60 mg Once Daily versus Placebo in Generalized Anxiety Disorder. A Randomized, Double-Blind, Placebo-Controlled, and Drug-Controlled, Fixed-Dose, Parallel-Group, Multi-Center Study of 10 Weeks (Including a 2-Week, Single-Blind Placebo Period). (PM.108) 2002

A 6-Week, Double-Blind, Randomized, Multi-Center, Fixed-Dose, Placebo-Controlled Study of Drug Dosed Twice a Day in Patients with Generalized Anxiety Disorder. (PR.101) 2001

A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dosage Trial to Evaluate the Efficacy and Tolerability of Drug in Patients with Generalized Anxiety Disorder (GAD). (GK.105) 2001

A Placebo-Controlled Study of Drug Dosed BID and TID in Patients with Generalized Anxiety Disorder. (PD.103) 2000

Open-Label, Safety Study of Drug in Patients with Anxiety Disorders. (PD.104) 1999

**CLINICAL TRIAL EXPERIENCE (continued):**

***Binge Eating Disorder***

A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, & Tolerability of Drug in Adults with Moderate to Severe Binge Eating Disorder. (SU.108) 2017

An Open-label, Flexibly-dosed, Multicenter, Extension Study of Drug to Evaluate Long-term Safety and Tolerability in Adults with Binge Eating Disorder. (SU.107) 2015

A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexibly-dosed, Multicenter Study to Evaluate the Efficacy, Safety, & Tolerability of Drug in Adults with Moderate to Severe Binge Eating Disorder. (SU.106) 2015

***Bipolar Disorder***

A Phase III, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Fixed-dose Clinical Trial Evaluating the Efficacy, Safety and Tolerability of Drug in Patients with Bipolar I Depression. (FL.111) 2016

A Multi-Center, Randomized, Parallel-Group, Double-Blind, Phase III Comparison of the Efficacy and Safety of Drug (oral tablets 400 mg to 800 mg daily in divided doses) to Placebo When Used as Adjunct to Mood Stabilizers (Drug or Drug) in the Maintenance Treatment of Bipolar I Disorder in Adult Patients. (AA.102) 2003

***Cardiovascular***

Follow-Up Serial Infusions of Drug for the Management of Patients with Heart Failure - STUDY II. 2004

Management of Patients with Congestive Heart Failure after Hospitalization, Follow-Up Serial Infusions of Drug, a pilot study. 2002

***Depression***

A Phase II, Depression Diagnostic Aid Confirmatory Performance Study - An Abbreviated Investigational Device Exemption Study

A Double-Blind, Placebo- and Active-Controlled Evaluation of the Safety and Efficacy of Drug in Adolescent Patients with Major Depressive Disorder. (AN.105) 2017

A Randomized, Double-blind, Active-controlled Trial to Assess the Efficacy and Safety of Drug Administered Orally to Subjects with Treatment Resistant Major Depressive Disorder. (AS.101) 2016

**CLINICAL TRIAL EXPERIENCE (*continued*):**

A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of *Drug* (5, 10 and 20 mg) in Adults With Major Depressive Disorder (MDD). (TG.112) 2015

A Phase III, Multicenter Study of the Long-term Safety and Tolerability of *Drug* for the Adjunctive Treatment of Major Depressive Disorder in Adults Who Have an Inadequate Response to Antidepressant Therapy. (AK.103) 2014

A Multi-centre, Double-blind, Randomized-withdrawal, Parallel-group, Placebo-controlled, Phase III Study of Efficacy and Safety of *Drug* as Monotherapy in the Maintenance Treatment of Patients with Major Depressive Disorder (MDD) Following an Open-Label Stabilisation Period (XXX STUDY). (AA.107) 2006

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of *Drug* in Subjects with Major Depressive Disorder. (GK.122) 2004

A Phase III, 8-Week, Double-Blind, Randomized Study of the Efficacy and Safety of *Drug* plus *Drug* in Combination as Compared to *Drug* and *Drug* Monotherapies in Patients with Treatment Resistant Recurrent Major Depressive Disorder. (EL.106) 2004

A Double-Blind, Flexible-Dose Comparison of *Drug*, *Drug*, and Placebo in the Treatment of Major Depressive Disorder. (FL.103) 2003

A Double-Blind, Multi-Center, Placebo-Controlled Study of *Drug* in the Treatment of Patients with Major Depressive Disorder. (MC.103) 2003

A Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of a Once-Daily Oral *Drug* (20-40-60 mg) versus Placebo in Subjects with Major Depressive Disorder Over an Eight-Week Treatment Period. (GK.114) 2003

An Open-Label, Extension Trial in Children and Adolescents with Major Depressive Disorder Who Participated in One of the Short-Term *Drug* Safety and Efficacy Trials. (OG.102) 2003

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Safety and Efficacy Trial of *Drug* in Outpatient Children and Adolescent with Major Depressive Disorder. (OG.101) 2003

An 8-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multi-Center, Fixed-Dose Study Comparing the Efficacy and Safety of *Drug* or *Drug* to Placebo in Moderately to Severely Depressed Patients with Major Depressive Disorder. (GK.107) 2002



**CLINICAL TRIAL EXPERIENCE (*continued*):**

A Study to Evaluate the Efficacy, Safety, and Maintenance Effect of Drug Augmentation of Drug Monotherapy in Young and Older Adult Patients with Unipolar Treatment-Resistant Depression. (JN.101) 2002

A Double-Blind, Multi-Center, Placebo- and Active-Controlled, Acute and Extension Study of Two Doses of Drug in the Treatment of Patients with Major Depressive Disorder. (MC.101) 2001

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating Efficacy and Safety of Three Doses of Drug versus Placebo in Patients with Major Depressive Disorder. (SB.108) 2001

A Double-Blind, Placebo-Controlled, Fixed-Dosage Study Comparing the Efficacy and Tolerability of Drug and Drug to Placebo in the Treatment of Major Depressive Disorder with Anxiety. (GK.104) 2001

***Fibromyalgia***

A Phase IIa, Randomized, Double-Blind Placebo-controlled, Parallel-group Study to Assess the Analgesic Efficacy and Safety of XXX in Patients with Fibromyalgia (AT.101) 2017

A Phase III, Double-blind, Randomized, Multicenter, Placebo-controlled Study to Evaluate the Efficacy and Safety of Drug Tablets Taken Daily at Bedtime in Patients with Fibromyalgia. (TX.101) 2016

An Open-label Extension Study of Drug for 52 Weeks in Pain Associated with Fibromyalgia. (DS.103) 2015

***Hypertension***

A Randomized, Double-blind, Placebo-controlled, Forced-titration, Phase IV Study Comparing Drug 80 mg + Drug 25 mg versus Drug 160 mg + Drug 25 mg Taken Orally for Eight Weeks in Patients with Stage I or Stage II Hypertension. (BI.102) 2005

A Multi-Center, Double-Blind, Randomized, Parallel-Group Study to Evaluate the Effects of Drug and Drug on Microalbuminuria in Mild to Moderate Hypertensive Subjects with Type 2 Diabetes Mellitus. (NO.107) 2003

Drug Cardiovascular Treatment Assessment Versus Drug (Study). (BS.105) 2000

**CLINICAL TRIAL EXPERIENCE (*continued*):**

***Insomnia***

Efficacy and Safety of Drug 5mg/day for Sleep Maintenance Insomnia: a 12-week, Multi-center, Randomized, Double-blind, Placebo-controlled Study Followed by an Open-treatment, Phase Extension with Drug for a 40-week Period. (SV.102) 2006

The Efficacy of Drug 3mg as Adjunctive Therapy in Subjects with Insomnia Related to Generalized Anxiety Disorder (GAD). (SE.102) 2005

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 8-Week, Safety and Efficacy Study of Drug 3 mg Compared to Placebo in Subjects with Insomnia Related to Major Depressive Disorder. (SE.101) 2003

***Irritable Bowel Syndrome***

A Phase IV Multicenter, Multinational, Prospective, Randomized, Placebo-Controlled, Double-Blinded Parallel Group Study to Assess Efficacy of *Drug* in the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Patients Who Report Inadequate Control of IBS-D Symptoms with Prior Loperamide Use. (AN.106) 2017

***Men's and Women's Health***

A Placebo-Controlled, Double-Blind, Randomized, Parallel Study of the Withdrawal Effects of Chronic Daily and As Needed Dosing with Drug in the Treatment of Premature Ejaculation. (JO.101) 2005

A 12-Week, Multi-Center, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Active-Controlled, Escalating-Dose Study to Compare the Effects on Sexual Functioning of Drug (150-450 mg/day) and Drug (75-225 mg/day) in Subjects with Major Depressive Disorder. (GK.121) 2004

A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy of a Monophasic Oral Contraceptive Preparation, Containing Drug, in the Treatment of Premenstrual Dysphoric Disorder (PMDD). (BX.101) 2000

A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of Drug Continuous Treatment (12.5 mg and 25 mg/day) for Premenstrual Dysphoric Disorder. (SB.102) 2000

Genital Herpes Oral Suppression Trial of Drug vs. Placebo. 1999

Drug vs. Placebo to Assess Efficacy and Safety in Patients with Recurrent Herpes Labialis. 1999

Drug vs. Placebo to Assess Safety and Efficacy in Patients with Recurrent Genital Herpes. 1999

**CLINICAL TRIAL EXPERIENCE (*continued*):**

A Comparison of the Efficacy and Safety of Oral Drug for the Treatment of Pyelonephritis or Complicated Urinary Tract Infections. 1999

A Comparison of the Efficacy and Safety of Drug Given Either as a Single Oral Dose of 640 mg or as 320 mg Twice Daily vs. Oral Drug 250 mg Twice Daily for the Treatment of Uncomplicated Urinary Tract Infections in Females. 1999

***Migraine***

A Multicenter, Open Label, Long-Term Safety Study of XXX in Patients with Acute Migraines

A Phase III, Double-Blind, Randomized, Placebo Controlled, Safety, Efficacy, Trial of XXX for the Acute Treatment of Migraine (BH.102) 2017

A Phase III, Double-Blind, Randomized, Placebo Controlled, Safety, Efficacy, Trial of XXX for the Acute Treatment of Migraine (BH.101) 2017

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy, Tolerability and Safety Study of XXX in Episodic Migraine With or Without Aura (DL.101) 2017

A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral XXX in Episodic Migraine Prevention (AN.104) 2016

A Multicenter, Randomized, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral XXX in the Acute Treatment of Migraine With or Without Aura (AN.103) 2016

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Single Attack Study to Evaluate the Efficacy, Safety and Tolerability of Oral XXX in the Acute Treatment of Migraine (AN.102) 2016

A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of *Drug* for the Preventive Treatment of Migraine. (TV.103) 2016

A Randomized, Double-blind, Multi-center, Placebo-controlled, Cross-over Study to Determine the Consistency of Response for Drug Administered During the Mild Pain for the Acute Treatment of Multiple Migraine Attacks. (GK.126) 2005

Drug Intervention to Prevent Transformation of Episodic Migraine: The Drug XXX Study. (OM.104) 2005

**CLINICAL TRIAL EXPERIENCE (*continued*):**

A Randomized, Double-blind, Placebo-controlled, Single-attack, Parallel-group Evaluation of the Efficacy of Drug 100 mg Tablets versus Placebo in the Treatment of Subjects Who Affirm Tension, Tension-type, or Stress Headaches and Who Meet International Headache Society Criteria for Migraine. (GK.113) 2003

A Randomized, Double-Blind, Placebo-Controlled, Single-Attack, Parallel-Group Evaluation of the Efficacy of Drug 100 mg Tablets versus Placebo in the Treatment of Subjects Who Affirm Tension, Tension-type, or Stress Headaches, and Who Meet International Headache Society Criteria for Migraine. (PM.113) 2003

Open-Label, Long-Term, Multi-Center Study of Safety and Tolerability of Drug in the Acute Treatment of Migraines in Adults. (PM.111) 2002

A Phase III, Multi-Center, Randomized, Double-Blind, Parallel Group Study of Drug and Placebo in Patients with Multiple Moderate or Severe Acute Migraine Headaches. (PM.110) 2002

Multi-Center, Randomized, Double-Blind, Parallel-Group, Multiple-Dose Comparison Study of Drug, Drug, and Placebo in Patients with Moderate to Severe Acute Migraine Headache. (PM.106) 2001

***Oppositional Defiant Disorder***

A Phase III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Safety and Efficacy Study of Drug in Children and Adolescents Aged 6-17 with Oppositional Defiant Disorder (ODD). (SH.102) 2003

***Pain***

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to Evaluate the Long-Term Safety of Drug 0.5mg Twice Daily for 12 Months for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain. (GK.125) 2005

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Drug 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain. (GK.124) 2005

A 12-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study to Evaluate the Efficacy and Safety of Flexible Dosing of Drug at 500 mg to 1500 mg B.I.D. in the Treatment of Subjects with Painful Diabetic Neuropathy. (UP.101) 2001

**CLINICAL TRIAL EXPERIENCE (*continued*):**

***Post Traumatic Stress Disorder***

A Phase II, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled Trial of Drug (1 - 3 mg/day) as Monotherapy or as Combination Therapy in the Treatment of Adults with Post-traumatic Stress Disorder. (OT.110) 2017

A 12-Month, Open-Label, Flexible-Dosage Study to Evaluate the Safety of Drug at Dosages up to 16 mg/day in Adults with Chronic Post Traumatic Stress Disorder. (CP.107) 2003

A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dosage Study to Evaluate the Efficacy and Safety of Drug, at Dosages up to 16 mg/day in the Treatment of Chronic Post-Traumatic Stress Disorder (PTSD) in Adults. (CP.102) 2003

***Respiratory***

A Comparison of the Efficacy and Safety of Drug Given Either as Drug or Drug for the Treatment of Acute Bacterial Sinusitis. 1999

A Comparison of the Efficacy and Safety of Oral Drug for the Treatment of Acute Exacerbation of Chronic Bronchitis. 1999

Drug vs. Placebo to Assess the Efficacy and Safety of Drug (nasal spray), 5%, for the Prevention of Recurrent Acute Bacterial Sinusitis. 1999

***Other Indications***

A 6 ½-Month, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Comparison of Drug and Placebo for the Prevention of Seasonal Affective Disorder in Subjects with a History of Seasonal Affective Disorder. (GK.106) 2002

The Effect of Drug on Bone Mineral Density in Pediatric Patients with Anorexia Nervosa: A Double-Blind, Placebo-Controlled Study. (OM.101) 2002

A Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dose Study of Drug in Adolescent Outpatients with Panic Disorder. (WA.101) 2001

A Randomized, Double-Blind, Placebo-Controlled Study of Drug as Mono-Therapy Assessment of Reducing Cholesterol (STUDY). (PM.105) 2001

A Comparison of Drug vs. Drug in Patients Undergoing PCI (Percutaneous Coronary Intervention) Who Are at High Risk for Bleeding Complications. 2002

**COMMITTEES:**

Medication Oversight Committee , 01/2009 - Present  
Willamette Valley Hospice, Salem, OR

Quality Assurance and Performance Improvement Committee (QAPI), 01/2010 - 01/2013  
Willamette Valley Hospice, Salem, OR

**RESEARCH AND PUBLICATIONS:**

Potential of Infection by Epinephrine, Journal of Plastic and Reconstructive Surgery,  
December, 1985. Presented at the Annual Plastic and Reconstructive Surgery National Meeting,  
Detroit, MI, April, 1984.